Latest News by Industry
As part of the company's social responsibility pillar addressing the rapidly growing mental health crisis, Alexandria will present a critical conversation on the state of mental health in America with Patrick J. Kennedy at the Galien Forum at the Alexandria Center® for Life Science – New York City
NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, agtech and technology campuses in AAA innovation cluster locations with over 1,000 tenants, has forged a longstanding, impactful partnership with the Galien Foundation, the premier global institution dedicated to honoring innovative medicines and technologies through the Prix Galien Awards, one of the most prestigious prizes in the life science industry. Building upon this important relationship and shared commitment to improving human health and saving lives, Joel S. Marcus, Alexandria's executive chairman and founder, has been appointed to the Prix Galien USA Awards jury, a group of highly distinguished life science industry thought leaders with decades of proven experience across biopharma, healthcare, academia and venture capital. Mr. Marcus, alongside some of the most influential leaders in the life science industry, which include committee chair Roche director and former Wyeth chairman and CEO Bernard Poussot, Johnson & Johnson executive chairman Alex Gorsky and Pfizer chief scientific officer and global R&D president Mikael Dolsten, MD, PhD, is serving on the Prix Galien committee responsible for recognizing the Best Startup, Best Digital Health Solution and the inaugural Best Incubators, Accelerators and Equity. Winners of these categories will be announced today at the Galien Forum 2022, which will take place at the Alexandria Center® for Life Science – New York City, the city's first and only commercial life science campus.
"Joel and Alexandria have been exceptional strategic partners to the Galien Foundation for more than a decade, and we are thrilled to welcome Joel to our admired and highly curated Prix Galien Startup, Digital Health and Incubators, Accelerators and Equity committee this year," said Bruno Cohen, chairman of the Galien Foundation. "Under Joel's vision and leadership, Alexandria has become a leader and trusted partner within the life science industry. Joel's appointment to our jury is a testament to his tremendous contributions to the industry and the success of emerging life science companies, which are advancing human health in unprecedented ways."
Mr. Marcus pioneered the life science real estate niche with the founding of Alexandria in 1994 and is widely recognized for his extraordinary strategic, business, investment and legal contributions to the life science industry in driving forward transformative products that address significant unmet medical needs, as well as in creating and growing life science ecosystems that catalyze innovation. Prior to co-founding Alexandria, he had a well-established legal and business career during which he demonstrated unique and innovative expertise and creativity in the life science industry. Mr. Marcus was also one of the principal architects of Kirin-Amgen, Inc., the first and seminal biotechnology joint venture established in 1984 between Amgen Inc. and Kirin Brewery Company, Limited to fund the global development and commercialization of EPO (Epogen) and later G-CSF (Neupogen) — two blockbuster recombinant DNA products that have significantly benefited countless chronic kidney disease and cancer patients. An audacious entrepreneur, seasoned executive and astute venture capitalist with decades of experience serving on the boards of directors of several public and private life science companies and renowned industry and research organizations, Mr. Marcus brings extensive knowledge of cutting-edge science and strategic insights into company building to his role as a Prix Galien USA Awards juror.
"The Galien Foundation is at the forefront of fostering, recognizing and rewarding advances in biomedicine that positively impact the lives of patients around the world. We are immensely proud to be a longstanding strategic partner of the Galien as we continue to catalyze innovation across our life science ecosystems," said Mr. Marcus. "The life science industry, exemplified by our irreplicable roster of over 1,000 tenants, works tirelessly to address the 10,000 known diseases that affect us all, nearly 90% of which have no approved treatments. It is a tremendous honor to serve on the Prix Galien's esteemed awards jury as we celebrate the industry's most impactful medicines and products that are critical to meeting this massive unmet medical need."
In close collaboration with the Galien Foundation, Alexandria has made a distinctive impact on the annual Galien Forum and played a strategic role in its programming since the forum debuted in New York City in 2010. Over the past decade, Alexandria has curated and presented important panels featuring world-class subject matter experts to stimulate new approaches to the most important issues facing human health, including exploring how disruptive innovation can positively impact healthcare costs, the development of COVID-19 vaccines and the lifesaving role of an essential industry, as well as combating the devastating opioid crisis in America. This year, the company will present a timely conversation about the country's mental health crisis, featuring Patrick J. Kennedy, former congressman, founder of The Kennedy Forum, and one of the world's leading voices and policymakers on mental health. Co-moderated by Mr. Marcus and Alexandria's chief of science, Lynne Zydowsky, PhD, the discussion will explore critical issues, strategies and policies aimed at driving meaningful progress and revolutionizing the way mental illness is understood and treated. Each year in the United States, an estimated 1 in 5 adults will experience mental illness and 1 in 6 youth aged 6–17 will experience a mental health disorder, according to the National Alliance on Mental Illness (NAMI). Alexandria is addressing this persistent, widespread crisis, with a particular focus on helping children cope with suicide loss, through one of its eight social responsibility pillars.
"Now more than ever, it is our collective responsibility to normalize a national dialogue around mental health and do what it takes to increase access to care," said Mr. Kennedy. "It is a privilege to work closely with Alexandria, whose incredible initiative and partnership are instrumental in our efforts to build a more equitable, integrated healthcare system that embraces the body and the mind. We must bolster provider networks and scale and mobilize resources like never before to treat mental illness on the same level that we treat other illnesses such as cancer, HIV/AIDS, cardiovascular disease and, most recently, COVID-19. After all, there is no health without mental health. It's time to empower all Americans — especially our youth — from the inside out."
Alexandria aligns every aspect of its mission-driven business and visionary social responsibility efforts to advance human health and enhance the quality of people's lives. The company is steadfastly working to address some of society's most pressing issues through its eight core social responsibility pillars: (1) disease and other threats to human health and well-being, (2) hunger and food insecurity, (3) opioid addiction, (4) deficiencies in support services for the military and their families, (5) disparities in educational and character-building opportunities, (6) homelessness, (7) the loss of our nation's historical memory and (8) the mental health and suicide crisis.
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since its founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator and developer uniquely focused on collaborative life science, agtech and technology campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland and Research Triangle. The trusted partner to over 1,000 tenants, as of September 30, 2022, Alexandria has a total market capitalization of $33.3 billion and an asset base in North America of 74.5 million square feet, which includes 41.1 million RSF of operating properties and 5.6 million RSF of Class A properties undergoing construction, 9.9 million RSF of near-term and intermediate-term development and redevelopment projects and 17.9 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A properties clustered in life science, agtech and technology campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity and success. Alexandria also provides strategic capital to transformative life science, agrifoodtech, climate innovation and technology companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns and greater long-term asset value. For additional information on Alexandria, please visit www.are.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the potential impacts of Alexandria's social responsibility initiatives for the advancement of human health and the treatment of mental illness, and the success of Alexandria's tenants in connection with pursuing novel medicines. These forward-looking statements are based on the company's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by the company's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and the company assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in the company's forward-looking statements, and risks and uncertainties to the company's business in general, please refer to the company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.
CONTACT: Sara Kabakoff, Vice President – Strategic Communications, (626) 788‑5578,
skabakoff@are.com
SOURCE Alexandria Real Estate Equities, Inc.